Some of the most common peptides for weight loss belong to a class of drugs called glucagon-like peptide 1 (GLP-1) receptor agonists. These medications mimic the action of the natural hormone GLP ...

To support the development of next-gen therapies, including GLP-1 drugs for diabetes and obesity.

Iuliia Burmistrova/Getty Images The use of glucagon-like peptide-1 receptor agonists (GLP-1 agonists) for weight loss has been greatly increasing. Past studies show there are positive and negative ...

NH2-terminal GIP immunoreactivity was measured using the specific antiserum 98171, which cross-reacts <0.1% with GIP3-42 or with structurally related GLP peptides or glucagon. Addition of ...

The study included nearly 2 million patients, making it the largest ever conducted on this group of glucagon-like peptide-1 receptor agonists. All the participants, who were followed for a median ...

A new peer-reviewed study based on data from nearly 2M individuals highlights a wide range of clinical benefits and risks, including several newly found conditions linked to the GLP-1 class of ...

Share on Pinterest GLP-1 drugs may improve brain and heart health but could cause problems for the kidneys and pancreas, according to a new study. FreshSplash/Getty Images Researchers report that ...

Attribution (BY): Credit must be given to the creator. Lipidated analogues of glucagon-like peptide 1 (GLP-1) have gained enormous attention as long-acting peptide therapeutics for type 2 diabetes and ...

In this article, we are going to take a look at where Global Partners LP (NYSE:GLP) stands against other oil & gas stocks that are skyrocketing so far in 2025. The oil & gas sector has been quite ...

Over a median of 3.68 years, adults with type 2 diabetes who added a GLP-1 agent to their treatment plan had significantly decreased risks for 42 diverse outcomes, increased risks for 19 outcomes ...